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The initial wave of antibody production after 
challenge with T-dependent antigen is produced 
by plasma cells generated from the rapid extra-
follicular proliferative focus response (1). Antigen-
specifi  c B cells are initially expanded through 
collaboration with CD4+ T helper cells at the 
interface between the T and B zones (2–4). 
After 3–4 d, activated B cells can migrate to the 
bridging channels and red pulp of the spleen 
and form extrafollicular foci. Here they diff  eren-
tiate into plasma cells, many of which are short 
lived (5) and secrete antibodies that may be ei-
ther switched (e.g., IgG1) or unswitched (IgM; 
references 1, 6). B cells do not undergo somatic 
hypermutation (SHM) before or during the ex-
trafollicular response; the resultant antibodies be-
ing comprised almost exclusively of specifi  cities 
encoded within the primary repertoire (5, 7). 
A second wave of T-dependent plasma cell pro-
duction is subsequently   derived from responding 
B cells that, instead of colonizing extrafolli-
cular foci, enter the primary follicle and propo-
gate within the germinal center (GC) reaction. 
In GCs, responding B cells collaborate with fol-
licular T helper and dendritic cells to undergo 
SHM (8) with mutant clones that recognize the 
immunogen with increased affi   nity being selec-
tively propagated   (affi   nity maturation; reference 9). 
Plasma cells that contribute to the later post-GC 
phase of antibody production therefore typically 
express somatically mutated Ig genes (10).
The decision between extrafollicular plasma 
cell diff  erentiation and GC migration represents 
the fi  rst major branch point during a T-dependent 
B cell response. Nevertheless, the physiologi-
cal cues responsible for directing B cells down 
one pathway versus the other are currently un-
known (1). One theory is that responding cells 
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stochastically follow either response pathway such that the 
original specifi  cities recruited into the response are repre-
sented equally in both the extrafollicular and early GC pop-
ulations (11, 12). Alternatively, diff   erential recognition of 
antigen by B cell receptors (BCRs) expressed on individual 
B cells may infl  uence their subsequent responses, in which 
case the specifi   cities represented in the extrafollicular and 
early GC populations would diff  er. Evidence for the stochas-
tic model has come from analysis of responses to the hapten 
(4-hydroxy-3-nitrophenyl)acetyl (NP), where both low and 
high affi   nity clones have been detected at similar frequen-
cies in extrafollicular foci and early GCs (11). However, the 
stochastic model is diffi   cult to reconcile with data from other 
systems, indicating that relatively high affi   nity specifi  cities can 
dominate the initial T-dependent antibody response (13–15). 
The question of whether the nature of the interaction 
  between antigen and BCR infl  uences cell fate during early 
T-dependent responses is therefore still controversial.
The two major variables that impact on the interaction of an 
antigen with a BCR are the affi   nity of the epitope for the recep-
tor’s monovalent Fab and the density or valency of the epitope 
on the antigen. Manipulation of either of these variables can 
produce profound changes in the responses of B cells to BCR 
stimulation in vitro (16–19) as well as to T-independent re-
sponses (20, 21) and induction of self-tolerance (22–24) in vivo. 
The uncertainty surrounding the impact of antigen affi   nity and 
density on early T-dependent B cell responses is due largely to 
the diffi   culty of tracking responding B cells in vivo and defi  ning 
the precise nature of their initial interaction with the antigen. 
To overcome these problems, we have developed gene-targeted 
mice expressing H and L chains of HyHEL10 anti–hen egg ly-
sozyme (HEL) mAb (SWHEL), in which B cells express a defi  ned 
anti-HEL BCR and are capable of normal Ig class switching and 
SHM (6, 25). By challenging CD45-allotyped marked SWHEL 
B cells with HEL coupled to sheep red blood cells (SRBC) in an 
adoptive transfer system, T-dependent responses can be accu-
rately tracked in vivo by both immunohistology and fl  ow cyto-
metry (6). In this study, SWHEL B cells were challenged with a 
range of recombinant HEL proteins engineered to recognize the 
SWHEL BCR over a 10,000-fold affi   nity range and coupled to 
SRBC at diff  erent antigen densities. Examination of the early 
T-dependent responses generated by the SWHEL B cells indi-
cated that decreasing either antigen affi   nity or density profoundly 
reduced the extrafollicular plasma cell response but had minimal 
impact on the GC reaction. Thus, although the requirements for 
GC entry are not stringent, responding B cells require a strong 
initial interaction with the antigen to contribute signifi  cantly to 
the early plasma cell response. These results reveal that the initial 
antigen–BCR interaction plays a fundamental role in organizing 
early T-dependent B cell responses.
RESULTS
Generation of HEL mutants with varying affi  nities 
for the SWHEL BCR
The role played by initial antigen affi   nity in regulating early 
B cell responses was investigated by generating a panel of 
  recombinant HEL molecules with the capacity to bind over 
a wide affi   nity range to the anti-HEL BCR expressed on 
SWHEL B cells. SWHEL mice carry a targeted Ig heavy chain 
variable region gene with a light chain transgene that together 
encode BCRs with the specifi  city of the HyHEL10 mAb 
(25). Because the affi   nity of WT HEL for HyHEL10 is very 
high (2 × 1010 M−1) (26), it was necessary to create HEL 
mutants that bound HyHEL10 with lower affi   nities more 
typical of those found in primary B cell responses. Arginine 
21, arginine 73, and aspartate 101 of HEL all form direct con-
tacts with the Ig heavy chain of HyHEL10 (reference 26; Fig. 
1 A) and were mutated to glutamine (R21HELQ), glutamate 
(R73HELE), and arginine (D101HELR) both singly and in 
combination. Recombinant HEL mutants were expressed in 
yeast and purifi  ed from culture supernatants. All retained lyso-
zyme enzymatic activity and diff  ered less than twofold from 
WT HEL (HELWT) in their affi   nity for the noncompetitive 
anti-HEL mAb HyHEL9 (unpublished data), indicating that 
these point mutations did not aff  ect overall protein folding.
As expected, the affi   nities of the various HEL mutants for 
HyHEL10 varied widely. Competitive ELISA studies showed 
that mutant HEL containing only the D101HELR substitution 
(HEL1X) bound with  80-fold lower affi   nity than HELWT to 
HyHEL10 (Fig. 1 B), which is in agreement with previous 
studies (27). Addition of R73HELE to D101HELR (HEL2X) de-
creased this affi   nity   3-fold, whereas subsequent addition 
of R21HELQ (HEL3X) reduced it a further  50-fold. Because 
HEL1X and HEL2X displayed similar affi   nities for HyHEL10, 
only HELWT, HEL2X, and HEL3X were used in subsequent 
analyses. Based on previous data (18, 26, 27) and our compet-
itive ELISA results, we estimated the affi   nities of the recom-
binant HEL proteins for HyHEL10 to be as follows: 2 × 1010 
M−1 (HELWT), 8 × 107 M−1 (HEL2X), and 1.5 × 106 M−1 
(HEL3X). The relative affi   nity measurements of these mutant 
proteins are also in agreement with the amount of soluble 
protein needed to stimulate B cells in vitro. Thus, when acti-
vation of purifi  ed splenic B cells from SWHEL.rag1−/− (28) 
mice was analyzed, 10- and 1,000-fold higher concentrations 
of HEL2X and HEL3X, respectively, were required to induce 
comparable levels of intracellular tyrosine phosphorylation to 
that triggered by HELWT (Fig. 1 C). These recombinant pro-
teins therefore provide the basis for comparing the in vivo 
responses of SWHEL B cells to high affi   nity (HELWT), inter-
mediate affi   nity (HEL2X), and low affi   nity (HEL3X) antigens.
SWHEL B cells proliferate and form GCs in response 
to antigens encompassing a 10,000-fold affi  nity range
To compare T cell–dependent responses to the various HEL 
proteins, we used a previously described system in which 
small numbers (104) of anti-HEL B cells from C57BL/6 
(CD45.2+) SWHEL donor mice are adoptively transferred into 
nonirradiated C57BL/6 congenic (CD45.1+) recipients and 
challenged intravenously with HEL conjugated to SRBC (2 × 
108) in the absence of additional adjuvant (6). HEL is linked 
to SRBC to recruit SRBC-specifi  c T cell help to the SWHEL 
donor B cells because HEL itself cannot elicit a T cell response JEM VOL. 203, April 17, 2006  1083
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on the C57BL/6 genetic background (29). In this system, 
the T cell–dependent response of SWHEL donor B cells can 
be precisely tracked by multiparameter fl   ow cytometry 
based on CD45.2 and HEL-binding BCR expression (6). As 
the recipient mice are nonirradiated, responding B cells can 
navigate normally through intact peripheral lymphoid 
tissues where their localization can be readily visualized by 
immunohistology (6).
We fi  rst tested the ability of SWHEL B cells to initiate a 
primary in vivo response when challenged with SRBC con-
jugates of the various recombinant HEL proteins. Adoptive 
transfers were performed using CFSE-labeled donor cells and 
proliferation of the HEL-binding donor cells was measured 
64 h later. Extensive proliferation was observed in response 
to HELWT-SRBC, HEL2X-SRBC, and HEL3X-SRBC (Fig. 2). 
These responses were antigen specifi  c because they did not 
occur upon challenge with mock-conjugated SRBC (Fig. 2). 
Although antigen affi   nity had some eff  ect on the degree of 
proliferation observed (Fig. 2), SWHEL B cells nevertheless 
responded effi   ciently to SRBC conjugates of all three recom-
binant proteins.
We next examined the ability of the SWHEL donor B cells 
challenged with the various recombinant HEL proteins to 
diff  erentiate into GC B cells. By day 5, immunohistological 
analysis of spleen sections confi  rmed that there was consider-
able expansion of HEL-binding B cells in response to each of 
the recombinant HEL proteins, whereas none was evident in 
mice challenged with mock-conjugated SRBCs (Fig. 3). Re-
sponding HEL-binding B cells were derived from adoptively 
transferred donor SWHEL B cells because they were not de-
tectable in mice that were challenged with any of the HEL-
SRBC conjugates in the absence of cotransferred SWHEL 
B cells (unpublished data). HEL-binding B cells were found 
within PNA+ GCs from recipients challenged with each of 
the three HEL-SRBC conjugates (Fig. 3). By fl  ow cytome-
try, donor-derived GC B cells were identifi  ed on the basis of 
Figure 1.  Comparison of the abilities of recombinant HEL proteins 
to bind to and signal through HyHEL10 in vitro. (A) Rasmol space-
fi  lling model of HEL showing the mutated residues (colored) within the 
HyHEL10-binding footprint (light blue). (B) Competitive ELISA showing 
relative inhibition of the binding of HELWT-biotin to HyHEL10 by varying 
concentrations of recombinant HEL proteins. The half-maximal inhibitory 
concentration for each HEL protein was used to calculate the relative 
affi  nities for HyHEL10. (C) Western blot of intracellular tyrosine phosphor-
ylation (pTyr) after 15-min stimulation of SWHEL.rag1−/− B cells with vary-
ing concentrations of recombinant HEL proteins. Blue, HELWT; orange, 
HEL1X (D101HELR); green, HEL2X (R73HELE, D101HELR); red, HEL3X (R21HELQ, 
R73HELE, and D101HELR). Figure 2.  SWHEL B cells make in vivo proliferative responses to 
SRBC conjugates of all three recombinant HEL proteins. SWHEL B cells 
(CD45.1+) were labeled with CFSE and challenged with various HEL-SRBC 
conjugates by adoptive transfer into CD45.2+ congenic recipients. 
(A) Pseudocolor FACS plots show the CFSE profi  le of donor HEL-binding 
SWHEL B cells in recipient spleens 64 h after challenge with the various 
HEL-SRBC conjugates. The data shown were gated from total splenocytes 
after staining with anti–CD45.1-PE. Numbers indicate the frequency of 
HEL-binding CFSE+ cells among total splenocytes. Data includes a high 
frequency of contaminant cells (non-HEL binding and CFSE−) present in 
this analysis as a result of background staining by the anti–CD45.1-PE 
antibody. Note the lack of proliferating non-HEL–binding cells, indicating 
that proliferation is antigen specifi  c and that the HEL-binding stain de-
tects all responding SWHEL donor B cells. (B) CFSE profi  les are shown for 
HEL-binding cells present in the gates shown in A. The frequencies of 
undivided (CFSEhi) cells are shown. Note the increased frequency of divid-
ing cells and their enhanced rate of proliferation (CFSE dilution) as affi  n-
ity for the HEL antigen is raised.1084  ANTIGENIC CONTROL OF EARLY B CELL RESPONSES | Paus et al.
high surface CD45.2 and HEL binding, relatively low intra-
cellular HEL binding, and lack of syndecan-1 (CD138) ex-
pression (Fig. 4). These cells also expressed high levels of GL7 
and Fas (CD95; unpublished data). Quantifi  cation of the 
  responses to HELWT-SRBC, HEL2X-SRBC, and HEL3X-
SRBC revealed that challenge with all three antigens elicited 
similar numbers of donor-derived (CD45.2+) GC B cells by 
day 5 (Fig. 5 A). SWHEL donor B cells responding to HEL-
SRBC conjugates therefore proliferated and diff  erentiated 
into GC B cells largely independently of the 10,000-fold 
variation in their initial affi   nity for the three recombinant 
HEL antigens.
Initial BCR affi  nity regulates the extrafollicular 
plasma cell response
Variation of antigen affi   nity, although not aff  ecting GC B cell 
diff  erentiation, did have a profound impact on the diff  erenti-
ation of SWHEL B cells into extrafollicular proliferative focus 
plasma cells. Thus, histological analysis of recipient spleens at 
day 5 revealed that cells exhibiting a plasma cell phenotype 
(large size and intense cytoplasmic HEL staining) accumu-
lated in the splenic bridging channels and red pulp of mice 
challenged with HELWT-SRBC and HEL2X-SRBC but not 
in mice challenged with HEL3X-SRBC (Fig. 3). By fl  ow cyto-
metry, these plasma cells were identifi  able on the basis of 
lower surface CD45.2 and HEL binding compared with GC 
B cells, very high intracellular HEL binding, and high syn-
decan-1 expression (Fig. 4). At the peak of the extrafollicular 
response on day 5, recipients immunized with HELWT-
SRBC and HEL2X-SRBC contained >100-fold more splenic 
plasma cells than those challenged with low affi   nity HEL3X-
SRBC (Fig. 5 B). This was refl  ected in the relative levels of 
both total and IgG1 anti-HEL serum antibodies present at 
this time point (Fig. 5 C and not depicted). These antibodies 
were derived from the SWHEL donor B cells because they 
were not detected in mice challenged with any of the HEL-
SRBC conjugates in the absence of cotransferred SWHEL 
B cells (unpublished data). Day 5 plasma cells generated in re-
sponse to HELWT-SRBC and HEL2X-SRBC were confi  rmed 
to have originated from extrafollicular foci by the absence of 
Ig heavy chain variable gene mutations (0/20 and 0/22 clones 
carried mutations, respectively) in contrast to the SHM al-
ready present in corresponding GC B cell populations (10/24 
and 4/18 clones mutated, respectively). In this system, there-
fore, activated SWHEL donor B cells did not undergo diff  er-
entiation into extrafollicular plasma cells unless their initial 
Figure 3.  Antigen affi  nity controls the extrafollicular focus 
response. SWHEL B cells were adoptively transferred and challenged with 
either HELWT-SRBC (A), HEL2X-SRBC (B), HEL3X-SRBC (C), or mock-conju-
gated SRBC (D), and the spleens were harvested at day 5 for immunofl  uo-
rescence microscopy. B cells in the primary follicle are stained red with 
B220, GCs stained blue with peanut agglutinin, and HEL-binding Ig 
stained green with HEL. Anti-HEL plasma cells are evident from their in-
tense cytoplasmic staining with HEL. While HEL-binding B cells formed 
GCs in response to all three HEL conjugates, no HEL-binding extrafollicu-
lar foci of plasma cells were detectable in the spleens of mice challenged 
with HEL3X-SRBC. EF, extrafollicular focus; GC, germinal center; Fo, follicle; 
PALS, periarteriolar lymphatic sheath.
Figure 4.  Antigen affi  nity controls the generation of early plasma 
cells. Recipient mice were immunized as for Fig. 3 and spleens harvested 
for FACS analysis on day 5. (A) Surface staining for HEL-binding BCRs and 
the CD45.2 congenic marker shows two populations of responding donor 
B cells (CD45.2hi HEL bindinghi vs. CD45.2int HEL bindingint) in mice chal-
lenged with HELWT-SRBC and HEL2X-SRBC. Only the CD45.2hi HEL-bindinghi 
population is observed in mice challenged with HEL3X-SRBC. (B) Cytoplas-
mic staining for HEL-binding Ig reveals the CD45.2hi populations as low 
intracellular HEL-binding, syndecan-1− GC B cells, and the CD45.2int pop-
ulation as high intracellular HEL-binding, syndecan-1+ plasma cells (PC). 
Only rare donor-derived HEL-binding B cells with a plasma cell phenotype 
were detectable in mice immunized with HEL3X-SRBC. The proportion of 
spleen cells falling within the different PC and GC gates are indicated.JEM VOL. 203, April 17, 2006  1085
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antigen affi   nity exceeded a threshold value substantially higher 
than that required for GC B cell diff  erentiation.
Extrafollicular plasma cell differentiation is also regulated 
by epitope density
The regulation of extrafollicular plasma cell diff  erentiation by 
initial antigen affi   nity is indicative of a pivotal role for the 
BCR and its interaction with antigen in determining cell fate 
during early T-dependent B cell responses. Although antigen 
affi   nity alone may be the critical determinant, epitope density 
can also have a major impact on the strength of the inter-
action of antigen with the BCR and on subsequent B cell re-
sponses (16, 20, 23). To test whether epitope density as well as 
affi   nity aff  ects the decision to undergo early plasma cell versus 
GC B cell diff  erentiation, SWHEL B cells were challenged 
with SRBCs coupled to varying densities of the diff  erent 
  recombinant HEL proteins.
Our initial experiments (Figs. 3–5) indicated an apparent 
affi   nity threshold for early plasma cell diff  erentiation located 
between the affi   nities of HEL2X and HEL3X for the SWHEL 
BCR. To test the infl  uence of antigen density, we asked 
whether increasing the density of the low affi   nity HEL3X 
protein on the SRBC surface might rescue the extrafollicu-
lar plasma cell response to this protein and, conversely, 
whether reducing antigen density might abrogate the extra-
follicular response to the intermediate affi   nity  protein 
HEL2X. In addition to the standard SRBC conjugations us-
ing 100 μg/ml HEL2X or HEL3X, separate conjugations 
were performed using 1,000 μg/ml HEL3X and 10 μg/ml 
HEL2X. The antigen density on the diff  erent SRBC conju-
gates was compared by fl  ow cytometry using the HyHEL9 
mAb. The 100-μg/ml HEL2X and HEL3X conjugates were 
found to possess almost identical levels of surface antigen 
(intermediate density), whereas the density was increased 
threefold for the 1,000-μg/ml HEL3X conjugate (high den-
sity) and decreased fourfold for the 10-μg/ml HEL2X conju-
gate (low density; Fig. 6 A).
SWHEL B cells were challenged with the various conju-
gates in adoptive transfer and their responses analyzed on 
day 5. When equivalent densities of HEL2X and HEL3X were 
used (intermediate densities), affi   nity-based regulation of the 
early plasma cell response was again apparent, with 20- to 
30-fold more extrafollicular plasma cells and antibody being 
generated in response to HEL2X compared with HEL3X (Fig. 6, 
B and D–F). When the density of HEL3X on the SRBC 
was raised threefold (high density), the production of early 
plasma cells and the secretion of anti-HEL antibody in re-
sponse to this low affi   nity antigen were increased almost 10-
fold (Fig. 6, B and D–F). Conversely, decreasing the density 
of HEL2X by fourfold (low density) led to reductions of 5- to 
10-fold in the plasma cell and antibody responses to this in-
termediate affi   nity antigen (Fig. 6, B and D–F). Importantly, 
the magnitude of the early GC response did not vary greatly 
when antigen density was either raised or lowered (Fig. 6, B 
and C). As a result, the 12-fold diff  erence in epitope density 
between HEL2X-SRBC (low density) and HEL3X-SRBC 
(high density) negated the 50-fold affi   nity diff  erence between 
these antigens and resulted in almost identical day 5 responses 
(Fig. 6, B and C). Collectively, these fi  ndings indicate that it 
is the strength of the initial antigen–BCR interaction, infl  u-
enced by both epitope density and affi   nity, that determines 
the extent to which responding B cells enter the extrafollicu-
lar plasma cell response.
Affi  nity-based partitioning of competing B cells 
between the early plasma cell and GC compartments
Although the response of donor SWHEL B cells occurs within 
the context of an endogenous anti-SRBC antibody response, 
the monoclonal nature of the SWHEL BCR does not permit the 
simultaneous analysis of diff  erent B cell specifi  cities respond-
ing to the same antigen. The prediction from our fi  nding that 
the strength of the interaction between antigen and BCR 
  directs cell fate during early T-dependent responses is that 
B cells expressing alternative BCRs recognizing the same 
  epitope would be diff  erentially represented in the extrafollic-
ular plasma cell compartment depending on the strength of 
their initial interaction with the antigen. Because epitope 
density would in this case be fi  xed, our results predict that the 
Figure 5.  Intact GC but impaired extrafollicular focus and anti-
body responses to low affi  nity antigen. Recipient mice were immu-
nized as for Fig. 3 and analyzed 5, 10, 15, and 20 d later. (A) Enumeration 
of donor-derived GC B cells in the spleen by fl  ow cytometry shows similar 
numbers of GC B cells generated in response to all three HEL conjugates. 
(B) Enumeration of donor-derived plasma cells shows that the early, tran-
sient extrafollicular plasma cell response to HEL3X-SRBC is  100-fold 
lower than those to HELWT-SRBC and HEL2X-SRBC. (C) Serum anti-HELWT 
Igκ antibody levels were determined by ELISA and also found to be greatly 
abrogated in mice immunized with HEL3X-SRBC, particularly early in the 
response (day 5). No anti-HELWT antibody was detectable in control recipi-
ents that were immunized with any of the HEL-SRBC conjugates in the 
absence of cotransferred SWHEL donor cells (not depicted). Each data point 
represents one mouse. Each data point represents one mouse, whereas 
bars show the mean of each group. Blue, HELWT-SRBC; green, HEL2X-SRBC; 
red, HEL3X-SRBC; black, mock-conjugated SRBC.1086  ANTIGENIC CONTROL OF EARLY B CELL RESPONSES | Paus et al.
higher affi   nity B cells among competing specifi  cities will be 
preferentially represented in extrafollicular foci compared 
with early GCs.
To test this prediction, we moved out of the monoclo-
nal SWHEL model to take advantage of the fact that mice 
carrying the targeted heavy chain variable region gene of 
HyHEL10 without the light chain transgene (gene-targeted 
mice expressing only the H chain of HyHEL10 without 
the light chain transgene (SWHEL(H) mice) contain B cells 
with a range of affi   nities for HELWT due to pairing of the 
targeted heavy chain with diff  erent endogenous κ light chains 
(24). In particular, two B cell populations are resolvable 
by fl  ow cytometry using sub-saturating levels of HELWT, 
including a population of relatively high affi   nity (0.1–0.2% 
of B cells) and a second population with lower mean affi   nity 
for HELWT (0.2–0.4% of B cells; reference 24; Fig. 7 A). 
Comparisons of BCR binding by the various recombinant 
HEL proteins indicated that the affi   nity for HELWT of the 
latter (lower affi   nity) SWHEL(H) B cell population was still 
higher than the affi   nity of the SWHEL BCR for HEL3X 
(Fig. S2, available at http://www.jem.org/cgi/content/full/jem. 
20060087/DC1). For convenience, the second SWHEL(H) 
B cell population will be referred to as having intermediate 
  affi   nity for HELWT.
SWHEL(H) lymph node cells containing 104 anti-HEL B 
cells (high plus intermediate affi   nity) were adoptively trans-
ferred and challenged with HELWT-SRBC. As a control, 
SWHEL lymph node cells containing 104 anti-HEL B cells 
(high affi   nity only) were similarly transferred and challenged. 
Because the fraction of lymph node B cells that bind HEL in 
SWHEL mice is typically 5–15%, donor SWHEL lymph node 
cells were supplemented with a 25-fold excess of WT 
C57BL/6 lymph node cells so that anti-HEL B cells com-
prised a similar fraction (0.2–0.6%) of the SWHEL and 
SWHEL(H) donor B cell populations (Fig. 7 A). A further con-
trol group received only WT C57BL/6 lymph node donor 
cells and so lacked donor B cells with HEL-binding activity 
(Fig. 7 A). On day 5, CD45.2+, Igκ+ donor-derived B cells 
(including CD45.2lo, Igκlo plasma cells) were collectively an-
alyzed by fl  ow cytometry (Fig. 7 B). The cells were stained 
with a concentration of HELWT (75 ng/ml) that resolved the 
high and intermediate affi   nity SWHEL(H) responders. Cells 
were counterstained for surface Ig with anti-κ light chain to 
identify diff  erences in HELWT-binding caused by diff  erential 
antigen affi   nity rather than BCR expression level (Fig. 7 B). 
As expected, the anti-HELWT donor B cells evident in re-
cipients of SWHEL B cells fell almost exclusively within the 
high-affi   nity gate, whereas the only donor B cells detected in 
recip      i  ents of WT C57BL/6 lymph node donor cells were 
resting and did not bind HELWT (Fig. 7 B).
Analysis of recipients of SWHEL(H) cells indicated that both 
high and intermediate affi   nity anti-HEL donor B cell popu-
lations had been recruited into the response to HELWT-
SRBC (Fig. 7 B). Importantly, separate analysis of the two 
responding populations indicated that the proportion of the 
responding high affi   nity SWHEL(H) donor B cells that exhib-
ited a plasma cell phenotype was more than double that ob-
served among the intermediate affi   nity responders (i.e., 45 vs. 
21%; Fig. 7 C). Thus, as was predicted from our previous 
analysis of monoclonal T-dependent responses, the represen-
tation of competing B cells in the extrafollicular plasma cell 
response was greatest for those responders with the highest 
initial antigen affi   nity.
DISCUSSION
Diff  erential recognition of antigen by BCRs has long been 
recognized to play a key role in two specifi  c phases of T-de-
pendent B cell responses. The fi  rst is when resting B cells are 
selected to enter the response because this requires the inter-
action of the BCR with the foreign antigen to exceed a criti-
cal threshold. Subsequently, somatically mutated B cells 
generated within GCs are only propagated if they acquire in-
creased affi   nity for the antigen presented in immune com-
plexes on follicular dendritic cells. In between these two 
Figure 6.  Epitope density also controls the extrafollicular plasma 
cell response and early antibody production. (A) SRBCs were conju-
gated to HEL2X and HEL3X using 10, 100, or 1,000 μg/ml of recombinant 
protein to produce low, intermediate, and high epitope density immuno-
gens, respectively. The mean fl  uorescence intensity (mfi  ) of HyHEL9 stain-
ing is shown in each case. HyHEL9 recognizes both mutant HEL proteins 
equally well (not depicted). The open curve represents staining of mock-
conjugated SRBCs. (B) Spleens from recipient mice were harvested on 
day 5 and analyzed by fl  ow cytometry for cytoplasmic HEL binding and 
CD45.2 as for Fig. 4. Gates indicate the plasma cell (CD45.2int, high cyto-
plasmic HEL binding) and GC (CD45.2hi, low cytoplasmic HEL binding) 
responding populations, and the proportion of spleen cells in these gates 
are shown. (C–E) Donor-derived GC, plasma cells, and serum anti-HEL 
antibody were measured on day 5 of the different responses as for Fig. 5. 
Points represent data from individual recipients, whereas the bars show 
the mean of each group. The results show that, at a fi  xed antigen affi  nity, 
early plasma cell and antibody production vary directly according to anti-
gen density, whereas GC responses are relatively unaffected.JEM VOL. 203, April 17, 2006  1087
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checkpoints, however, responding B cells must decide 
whether to enter the GC reaction or undergo rapid plasma 
cell diff  erentiation in extrafollicular proliferative foci. In this 
study, we demonstrate that this decision is also controlled by 
the nature of the interaction between the BCR and antigen. 
Thus, we show that only responding clones that undergo a 
strong initial interaction with antigen can effi   ciently diff  eren-
tiate into extrafollicular plasma cells and contribute to the 
rapid early T-dependent antibody response.
The studies performed here required the production and 
purifi  cation of milligram amounts of the various recombinant 
HEL proteins. This was achieved using yeast expression and 
yielded protein preparations that were >95% pure. Never-
theless, the possibility existed that trace amounts of yeast-
  derived products with potential immunomodulatory eff  ects 
could infl  uence the results. We consider this to be very un-
likely for several reasons. First, the response observed here 
  after challenge with HELWT-SRBC is indistinguishable from 
that obtained when native, chicken egg–derived HEL is con-
jugated to SRBCs (6). Second, the characteristic responses 
obtained to each of the HEL mutants was consistent between 
batches of the same purifi  ed protein (unpublished data). 
  Finally, when high and intermediate affi   nity B cells competi-
tively responded to the same antigen in the same host, the 
predicted diff  erences in plasma cell production were still ob-
served (Fig. 7). Together, these observations indicate that our 
results were not aff  ected by the presence of any potential 
yeast contaminant.
The existence of an antigen-dependent threshold for early 
plasma cell production was initially evident in this study from 
the selective absence of the extrafollicular response when 
SWHEL B cells were challenged with the low affi   nity (Ka of 
 1.5 × 106 M−1) HEL3X-SRBC antigen (Figs. 1, 3, and 4). 
This result contrasts with the fi  ndings from previous studies 
on T-dependent B cell responses using the chemical hapten 
NP conjugated to chicken γ-globulin (CGG) carrier protein 
(NP-CGG). In this system, B cells with a range of initial anti-
NP affi   nities showed no diff  erential localization to extrafol-
licular foci versus early GCs (11, 30, 31). Indeed affi   nities as 
low as 105 M−1 are represented equally in both extrafollicular 
foci and early GCs generated after NP-CGG immunization 
(11). The results from the anti-NP system have led to the 
theory that diff  erentiation of responding B cells down the 
two early response pathways is essentially a stochastic process 
that operates independently of diff  erences in antigen recogni-
tion (11, 32). This model predicts that the initial burst of anti-
body production by extrafollicular plasma cells refl  ects the 
specifi  cities of all B cell clones recruited into the response and 
is therefore predominantly low affi   nity. Although this is in-
deed the case in anti-NP responses (5, 7), analysis of responses 
to viruses and natural protein epitopes indicates that the initial 
Figure 7.  Competing B cells partition into the extrafollicular 
plasma cell response according to their relative initial antigen 
affi  nity. (A) Flow cytometric analysis of lymph node B cells from WT 
C57BL/6, SWHEL, and SWHEL(H) mice. SWHEL cells were mixed with a 25-fold 
excess of WT C57BL/6 cells to equalize the frequency of HEL-binding 
cells between the SWHEL and SWHEL(H) samples. Cells were stained with 
75 ng/ml HELWT followed by HyHEL9-AlexaFluor647 and then counter-
stained for B220 and surface Ig (anti-κ light chain). Data represent 
B220+ cells. The diagonal gates indicate cells with proportional HELWT 
binding and surface Ig expression and, therefore, with similar or identi-
cal affi  nity for HELWT. The presence of populations with high and inter-
mediate affi  nity for HELWT are evident in SWHEL(H) mice. (B) Lymph node 
cells including 104 HELWT-binding B cells from SWHEL or SWHEL(H) mice 
were adoptively transferred into CD45.1 congenic recipients and chal-
lenged with HELWT-SRBC. Before injection, SWHEL lymph node cells were 
mixed 1:25 with WT C57BL/6 lymph node cells to ensure the anti-HEL 
B cells from SWHEL and SWHEL(H) mice comprised similar proportions of the 
respective donor B cell populations (0.2–0.6%). All recipients including 
the controls receiving just WT C57BL/6 lymph node cells (left) were 
therefore injected with  2 × 106 non-HELWT–binding B cells each. On 
day 5, splenocytes from recipient mice were stained with 75 ng/ml HELWT 
as for A and for CD45.2 and Igκ. Donor B cells were identifi  ed with a 
combination of gates that included CD45.2hi, Igκhi resting plus GC B 
cells, as well as CD45.2int, Igκint plasma cells. High and intermediate af-
fi  nity anti-HELWT B cells were identifi  ed as for A. (C) Donor B cells with 
high and intermediate affinity for HELWT from recipients of SWHEL(H) 
lymph node cells were analyzed separately for the plasma cell (PC) and 
GC phenotypes. The proportion of high affi  nity cells exhibiting the 
CD45.2int Igκint plasma cell phenotype was more than double that evident 
among the intermediate affi  nity responders. 1088  ANTIGENIC CONTROL OF EARLY B CELL RESPONSES | Paus et al.
burst of antibody production to T-dependent antigen is often 
of relatively high affi   nity (>107 M−1; references 13–15).
The disparate requirements for high antigen affi   nity in 
diff  erent T-dependent antibody responses can be reconciled 
by recognizing that it is the strength of the interaction be-
tween antigen and BCR that is crucial for regulating this 
process, rather than antigen affi   nity per se. This notion was 
confi  rmed in the present study by showing that SWHEL B 
cells could produce rapid plasma cell and antibody responses 
to the low affi   nity HEL3X-SRBC antigen when the density 
of HEL3X on the SRBC surface was increased (Fig. 6). The 
presence of low affi   nity clones in the extrafollicular focus re-
sponse to NP-CGG is therefore readily explained by the high 
epitope density on this haptenated protein antigen, which 
typically carries 16 NP groups per CGG monomer (31). Our 
results suggest, therefore, that B cells that recognize low af-
fi  nity epitopes can still interact suffi   ciently strongly with anti-
gen to enter the extrafollicular focus response but only if the 
epitope is present at relatively high density.
When epitope density is held constant, it is apparent that 
a 50-fold reduction in antigen affi   nity (i.e., HEL2X-SRBC to 
HEL3X-SRBC) can remove the extrafollicular plasma cell re-
sponse mounted by SWHEL B cells (Figs. 3–5). Smaller quan-
titative shifts in the strength of the interaction between the 
antigen and the BCR by either lowering the density of 
HEL2X or increasing the density of HEL3X on the SRBC sur-
face had signifi   cant but less absolute eff   ects on the early 
plasma cell response (Fig. 6). Similarly, SWHEL(H) B cells that 
bound HELWT with intermediate affi   nity were capable of elic-
iting a reduced but still clearly evident plasma cell response 
on day 5 (Fig. 7). Collectively, these results demonstrate that 
there is not a sharp threshold of interaction between antigen 
and BCR that determines whether or not early plasma cell 
diff  erentiation will occur. Rather, within a certain range of 
interaction strengths, the relative size of the early plasma cell 
response is directly related to the strength of that initial anti-
gen interaction.
Whether a strong interaction between BCR and antigen 
is universally required for extrafollicular focus formation is 
diffi   cult to assess without studying this question directly using 
other model antigens. The relatively high affi   nity of the early 
antibody response to several T-dependent antigens (13–15) is 
certainly consistent with BCR-dependent regulation of ex-
trafollicular plasma cell production also occurring in these 
cases. Nevertheless, it is possible that adjuvant or other modi-
fying factors alter the quantity or quality of BCR-indepen-
dent signals delivered to responding B cells by T cells and/or 
dendritic cells and that these may in turn override the BCR-
dependent controls described in the current study. It will be 
interesting to test this possibility in the future by challenging 
SWHEL B cells with the diff  erent mutant HEL proteins in 
  alternative immunogenic forms.
In contrast to T-dependent antigens, T-independent type 
2 (TI-2) antigens such as NP-Ficoll typically generate an ex-
trafollicular response only. Abortive GCs can be generated 
but only if antigen dose and precursor frequency are suffi   -
ciently high (33). This bias of TI-2 responses toward extrafol-
licular focus formation is also evident in the SWHEL system. 
Thus, when 104 HEL-binding SWHEL B cells are challenged 
with HELWT-Ficoll, short-lived extrafollicular plasma cells 
are generated but not GCs (unpublished data). If the observa-
tions of T-dependent responses in the current study can also 
be applied to TI-2 responses, it is possible to attribute the 
ability of TI-2 antigens to elicit a strong extrafollicular focus 
response to the fact that these antigens are typically highly 
cross-linking (34, 35) and therefore likely to interact strongly 
with the BCR. In this case, the failure of TI-2 antigens to ef-
fi  ciently generate GCs most likely refl  ects the importance of 
T cell help in potentiating GC formation. Alternatively, the 
strength of BCR engagement may eff  ect T-dependent and 
TI-2 responses diff  erently, potentially because of modulation 
in the latter case by co-stimuli delivered through CD21/35 
or Toll-like receptor molecules (36).
The fi  nding that quantitative diff  erences in antigen rec-
ognition regulate cell fate during early T-dependent B cell 
responses reveals a sophisticated level of control that has pre-
sumably evolved to optimize the deployment of responding 
B cell clones. Linking rapid plasma cell diff  erentiation to 
strong initial interaction with antigen means that the sub-
stantial resources required to support plasma cell diff  erentia-
tion and subsequent high level antibody production (37) are 
devoted only to those clones with a good chance of secret-
ing biologically eff  ective antibodies (38). In the case of pau-
civalent epitopes, this eff  ectively means that only relatively 
high affi   nity antibodies are produced (Figs. 2–4). However, 
epitopes present at high density may be eff  ectively neutral-
ized by antibodies of lower affi   nity (39–41). Under these 
specifi   c conditions (e.g., high density HEL3X-SRBC), it 
makes biological sense for low affi   nity B cells to be permit-
ted into the extrafollicular plasma cell response (Fig. 6). 
BCR-mediated regulation of early T-dependent responses 
also ensures that antigen-specifi  c specifi  cities that make min-
imal contribution to the initial antibody response are not 
discarded but specifi  cally directed to GCs. Here they can 
undergo SHM and affi   nity maturation and may contribute 
new eff  ective specifi  cities at a later stage of the response. 
This is exemplifi  ed when SWHEL B cells are challenged with 
intermediate density HEL3X-SRBC, where the absence of 
an early (day 5) antibody response (Fig. 5 C) is followed by 
the subsequent accumulation of high affi   nity  anti-HEL3X 
antibodies produced by somatically mutated post-GC plasma 
cells (unpublished data).
The critical role of a strong antigen–BCR interaction in 
early plasma cell diff  erentiation in vivo is intriguing given 
that B cells stimulated with T cell–derived signals in vitro 
undergo effi   cient proliferation-linked plasma cell diff  erentia-
tion without the need for BCR ligation (32). This dichotomy 
suggests that B cell diff  erentiation in vivo is infl  uenced by 
additional signals, which, in the absence of strong antigen 
recognition, suppress the default plasma cell diff  erentiation 
pathway. Because responding B cells can proliferate and enter 
the GC response without undergoing signifi  cant plasma cell JEM VOL. 203, April 17, 2006  1089
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diff  erentiation (e.g., HEL3X-SRBC response), it is possible 
that the GC microenvironment may inhibit this process. If 
this is true, a strong initial interaction between BCR and an-
tigen may allow at least a proportion of the daughter cells of 
a responding clone to bypass the GC and undergo plasma cell 
diff  erentiation. The specifi  c mechanism involved is not clear 
but may be based on BCR-mediated alterations in the ex-
pression of chemotactic receptors that facilitate extrafollicular 
migration (1). Alternatively, more effi   cient presentation of 
antigen-derived peptides facilitated by stronger antigen rec-
ognition may result in quantitative or qualitative diff  erences 
in the delivery of T cell help that infl  uence the subsequent 
B cell response. A potential clue may lie in the fact that the 
progressive lowering of initial antigen affi   nity reduced the 
rate of proliferation of the anti-HEL B cells during the fi  rst 
64 h of the response (Fig. 2). It is possible, therefore, that the 
initial proliferative response may infl  uence the ability of re-
sponding cells to undergo rapid plasma cell diff  erentiation. In 
this case it is possible that signals delivered independently of 
the antigen–BCR interaction but with the potential to mod-
ify B cell proliferation (e.g., Toll-like receptor ligands) may 
also impact on the size of the extrafollicular plasma cell re-
sponse. Studies using the model described here will assist in 
resolving the specifi  c mechanisms involved and further char-
acterize the signals that shape in vivo B cell responses. Such 
information holds great promise for the future development 
of novel therapies for autoimmune diseases as well as the op-
timization of vaccination strategies.
MATERIALS AND METHODS
Recombinant HEL proteins. cDNAs encoding the various mutant HEL 
proteins were produced by site-directed mutagenesis using engineered PCR 
primers. Sequences encoding the mature WT and mutant HEL proteins 
were then cloned directly 3′ of the secretory signal sequence in the yeast 
expression vector pPIC9K (Invitrogen). A COOH-terminal His(6) tag 
(SGHHHHHH) was included in each construct. Transformation of yeast 
(Pichia pastoris) and induction of recombinant HEL expression was per-
formed according to the manufacturer’s instructions. Recombinant HEL 
proteins were purifi  ed from yeast culture supernatants by ion-exchange 
chromatography using HiTrap SP FF columns followed by Ni2+ affi   nity 
chromatography (both from GE Healthcare). Recombinant HEL proteins 
were >95% pure as determined by SDS-PAGE and staining with Coo-
massie blue. Yields ranged from 5–15 mg of purifi  ed protein from 600 ml 
of culture supernatant.
Mice and adoptive transfers. SWHEL (25), SWHEL.rag1−/− (28), and 
SWHEL(H) (24) mice have been described previously. WT C57BL/6 and 
CD45.1 congenic C57BL/6 mice were obtained from the Animal Re-
sources Centre (Perth, Australia). All mice were maintained on a C57BL/6 
background and housed in specifi  c pathogen–free environment. All experi-
mental procedures were approved by the University of Sydney Animal 
  Ethics Committee. B cell isolation, CFSE labeling, and conjugation of HEL 
to SRBC were performed as described previously (6). SRBC conjugations 
were performed using recombinant WT or mutant HEL at 100 μg/ml unless 
otherwise indicated (Fig. 6). For adoptive transfers, spleen or lymph node 
cells from SWHEL or SWHEL(H) donor mice containing 104 HEL-binding 
B cells were injected intravenously into male CD45.1 congenic C57BL/6 
recipients together with 2 × 108 SRBC conjugated to a specifi  c recombinant 
HEL protein. Mock-conjugated SRBC in which HEL was omitted from the 
conjugation reaction served as a control antigen. No additional adjuvant was 
used in the immunizations. Mice receiving only HEL-conjugated SRBCs 
intravenously did not produce detectable anti-HEL serum antibodies, pre-
sumably because of the low frequency of anti-HEL B cells present in the 
  absence of transferred SWHEL B cells.
ELISAs. Anti-HEL antibody levels in sera from immunized mice were ana-
lyzed by ELISA as described previously (25). Competitive ELISA was per-
formed to measure the relative affi   nities of the mutant HEL for HyHEL10. 
For this, plates were fi   rst coated with purifi   ed HyHEL10, after which 
50 ng/ml of biotinylated HELWT was added in conjunction with varying con-
centrations of unlabeled recombinant HELWT, HEL1X, HEL2X, and HEL3X. 
Non-linear regression based on a one-site competition model was performed 
using GraphPad Prism software to fi  nd the curve-fi  t and calculate the half-
maximal inhibitory concentration.
Western blotting. SWHEL.rag1−/− B cells were isolated and stimulated 
with varying concentrations of recombinant HEL proteins for 15 min at 
37°C, and whole cell lysates were prepared in buff  er containing prote-
ase and phosphatase inhibitors as described previously (42). Proteins were 
separated by SDS-PAGE and membranes probed with mouse antiphos-
photyrosine (Upstate Biotechnology) followed by goat anti–mouse IgG–
horseradish peroxidase (Santa Cruz Biotechnology, Inc.) and developed 
with enhanced chemiluminescence (Perbio). Blots were stripped and re-
probed with anti-actin antibody (Santa Cruz Biotechnology, Inc.) to con-
trol for protein loading.
Immunohistology. Splenic sections were stained for GCs and HEL-bind-
ing B cells as previously described (6).
FACS analysis. Splenocytes were prepared, stained for surface molecules, 
and analyzed on a FACSCalibur (BD Biosciences) as previously described 
(6). Intracellular staining to detect cytoplasmic HEL-binding Ig was per-
formed after fi  xation with 10% formalin and permeabilization with 0.2% 
polyethylene sorbitan monolaurate. GC B cells (low intracellular HEL bind-
ing and syndecan-1 expression) and plasma cells (high intracellular HEL 
binding and syndecan-1 expression) were enumerated using the gates shown 
in Fig. 4 B. B cells in mice challenged with mock-SRBC fell in the GC 
B cell gate but were not counted as they had not proliferated (Fig. 2), did 
not express GL7 (not depicted), and were shown histologically to be absent 
from GC (Fig. 3 D).
SHM analysis. Single responding SWHEL B cells were sorted from the spleens 
of recipient mice 5 d after transfer using a FACSVantage (BD Biosciences). 
GC and plasma cells were identifi  ed using the gates shown in Fig. S1 (available 
at http://www.jem.org/cgi/content/full/jem.20060087/DC1) and single 
cells sorted into 96-well plates containing proteinase K (Sigma-Aldrich). The 
variable region exon of the SWHEL Ig (HyHEL10) heavy chain gene was then 
PCR amplifi  ed using Taq polymerase (Sigma-Aldrich) for 35 cycles with the 
primers G  T  T  G  T  A  G  C  C  T  A  A  A  A  G  A  T  G  A  T  G  G  T  G   and G  A  T  A  A  T  C  T  G  T  C-
C  T  A  A  A  G  G  C  T  C  T  G  A  G  . The primary PCR product was further amplifi  ed 
for 35 cycles with the nested primers T  T  G  T  A  G  C  C  T  A  A  A  A  G  A  T  G  A  T  G  G  T-
G  T  T  A  A  G  T  C   and C  A  A  C  T  T  C  T  C  T  C  A  G  C  C  G  G  C  T  C  . The fi  nal PCR pro-
duct was sequenced with the dideoxy-chain termination method using 
primer TTGTAGCCTAAAAGATGATGGTGTTAAGTC at the Australian 
Genomic Research Foundation (Brisbane, Australia). Sequences encoding 
the mature VDJ region were analyzed for the presence of SHM events.
Online supplemental material. Fig. S1 shows the FACS gating strategy 
for sorting single cells with the GC and plasma cell phenotypes. Fig. S2 
shows the binding of the various mutant HEL proteins to both SWHEL and 
SWHEL(H) B cells. Online supplemental material is available at http://www. 
jem.org/cgi/content/full/jem.20060087/DC1.
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